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Abstract
Background: Prion diseases are characterised by a neurodegenerative pattern in which the
function of immune system remains still elusive. In the present study, we evaluate if an exogenous
treatment with Interleukin-12 (IL-12) and IL-18, able to activate microglia, is able to affect scrapie
pathogenesis.
Results: Cytokines injected intracranially, induced a strong inflammatory response characterised
by TNF-α production and microglia activation. Two groups of mice were injected intracerebrally
with high dose of ME7 strain of scrapie containing IL-12 and IL-18 or sterile saline. Cytokines-
treated mice showed a more pronounced accumulation of PrPSc in brain tissues at 90 days post-
inoculation and a shorter mean survival times than untreated mice.
Conclusion: We can conclude that intracerebral administration of IL-12 and IL-18 can modulate
scrapie pathogenesis possibly through a microglia-mediated pattern.
Background
Prion diseases are characterised by a neurodegenerative
pattern represented by neuronal loss, vacuolation of neu-
rons and neuropil, and astrocytosis. They are character-
ized by the accumulation of an abnormal protein, named
PrPSc, which is formed postranslationally from the normal
isoform (PrPC). To date, the agent causing TSEs is still
incompletely characterized, although PrPSc is believed to
be its major if not unique constituent [1] which when
present as it has recent as small PrPSc aggregates are the
most efficient initiators of TSE disease [2].
A classical inflammatory response associated to the infec-
tion is lacking, as evidenced by the absence of proinflam-
matory cytokine upregulation [3], of a
polymorphonuclear leukocyte infiltration and perivascu-
lar cuffing of mononuclear cells around cerebral vessels or
any humoral or cellular immune response to infection
Published: 27 December 2006
BMC Veterinary Research 2006, 2:37 doi:10.1186/1746-6148-2-37
Received: 29 August 2006
Accepted: 27 December 2006
This article is available from: http://www.biomedcentral.com/1746-6148/2/37
© 2006 Pasquali et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Veterinary Research 2006, 2:37 http://www.biomedcentral.com/1746-6148/2/37
Page 2 of 9
(page number not for citation purposes)
[4,5]. Nevertheless, there is a large body of evidence that
immune system is involved somehow in the pathogenesis
of the disease [6,7]. Indeed, strong circumstantial evi-
dence of the involvement of immune system is provided
by the fact that a significant number of genes associated
with the immune response have shown increased expres-
sion in scrapie-infected mouse brains [8,9], that mice have
shown reduced susceptibility to scrapie after steroid
administration [10] and splenectomized mice have
shown prolongation of incubation time to scrapie [11]. In
analogy, in other experiments it has been reported that
susceptibility to scrapie was enhanced by aspecific stimu-
lators, such as phytohemagglutinin (PHA) [12].
In mouse models, follicular dendritic cells (FDC) are
involved in scrapie replication and neuroinvasion follow-
ing peripheral inoculation of scrapie agents is strongly
impaired in animals lacking these cells [13-15]. More
recently, it has been shown that also dendritic cells
acquire PrPSc in vitro, and transport directly into lym-
phoid tissues in vivo, suggesting that dendritic cells can
serve as a cellular bridge between the gut lumen and the
lymphoid compartment [16]. From that scenario it can be
envisaged a "Trojan-Horse" effect of these cells of the
immune system even if little is still known about their
activity in scrapie. It has been suggested that at least one
mechanism by which immune system is tightly involved
in prion infection is through the primary uptake of prion
protein, probably representing a narrow bridge between
the portal of entry of the prion protein and the peripheral
and the central nervous system [17]. Nevertheless, it was
also observed that skin-derived Langherans-like cells have
been shown to be able to degrade PrPSc in vitro [18] and
this findings contribute to the hypothesis that monocytic
cells can also have a protective effect against prions. All
together, these results clearly indicate that the relationship
between cells and prions is far to be completely elucidated
and possible dynamic relationships can determinate dif-
ferent outcomes. The interplay between scrapie agents and
the immune cells is even less understood in central nerv-
ous system. Microglia, which are the immunocompetent
cells that can be considered the equivalent of dendritic
cells [19], seem to be involved in the pathogenesis of the
disease [20] but their effective role is still under debate.
There is a large body of evidence, however, which suggests
that glial cells, through their secreted proinflammatory
cytokines contribute to prion-related neurodegenerative
processes [21-27]. Overall the gene array data demon-
strate the presence of a strong inflammatory reaction and
stress response in the late phase of the disease [28].
In the present study, we evaluate if the onset of the disease
can be modified by exogenous treatment with cytokines
known to act synergistically in promoting a proinflamma-
tory response [29], in order to better clarify the role of
immune cells in scrapie in the central nervous system of
mice.
Results
Effect of intracerebral administration of IL-12 and IL-18 on 
central nervous system
Mice were treated with cytokines or sterile saline, accord-
ing to protocols, and after 6 or 24 hours TNF-α and IFN-γ
production, along with PrPC expression, were monitored
in brain homogenates. In parallel an immunohistochem-
ical analysis of GFAP and F4/80 expression was performed
on paraffin embedded brain tissue.
IFN-γ and TNF-α were produced in mice stimulated both
with IL-12 and IL-18, even if with slight different patterns.
Mice inoculated with sterile saline produced a moderate
amount of IFN-γ and TNF-α but differences with
untreated mice were difficult to address due to the high
variability of the measured values. Mice injected with IL-
12 alone did not showed a significant increase of IFN-γ,
and only a slight increase of TNF-α (data not shown).
Mice injected with IL-18, showed a significant increase of
IFN-γ with at a lesser extent also an increase of TNF-α
(data not shown). Mice inoculated with IL-12 and IL-18,
finally showed a strong increase in the production of both
IFN-γ and TNF-α, with a more prominent effect after 24
hours of exposure (figures 1 and 2).
The expression of PrPC was assessed by western blot anal-
ysis in individual mice 6 and 24 hours after treatment and
compared with that of untreated mice. The administration
of IL-12 and IL-18 did not induce any change in the
expression of PrPC, neither at 6 or 24 hours after their
intracerebral administration (data not shown).
Immunohystochemistry was performed in basal nuclei,
thalamus, cerebellum and brain stem of mice enrolled in
the experiment. Immunostaining for GFAP and F4/80 was
used as indirect assessment of activation of astrocytes and
microglia, respectively.
GFAP positive astrocytes were present in the normal,
untreated brains and their number increased after treat-
ment with sterile saline. This increase was mainly evident
in the brain stem. The pattern of GFAP expression did not
change after treatments with IL-12 and IL-18 when com-
pared to saline (Table 1).
F4/80 positivity was barely detectable in brain paren-
chyma of normal, untreated mice. Reactive monocytes
located near brain vessels were also present and were con-
sidered perivascular macrophages. In mice treated with
saline there was a very slight increase in the number of
activated microglia, almost constant in all brain sections.
Mice treated with IL-12 and IL-18, showed a markedBMC Veterinary Research 2006, 2:37 http://www.biomedcentral.com/1746-6148/2/37
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increase in F4/80 microglia and perivascular macrophages
expression throughout the brain areas observed (Table 1).
Our findings indicate that IL-12 and IL-18 were able to
exert a substantial activation of microglia 6 and 24 hours
after their intracerebral administration.
Effect of intracerebral administration of IL-12 and IL-18 on 
the course of scrapie infection
To assess if an early activation of microglia, contemporary
to intracerebral scrapie inoculation, is able to modify the
course of scrapie infection, two groups of 22 mice were
infected with scrapie and treated with IL-12 and IL-18 or
sterile saline, respectively, according to protocols. After 90
days 6 animals from each group were sacrificed to indi-
rectly assess the progression of the infection by determin-
ing PrPSc brain accumulation. The remaining mice were
monitored to assess the mortality rate (Fig. 3). All inocu-
lated mice developed unequivocal clinical signs of scrapie,
starting after 125 days post-inoculation. There was a gen-
eral tendency of mice in the IL-12 and IL-18 treated group
to develop clinical symptoms earlier than untreated mice.
IL-12 and IL-18 treated mice started to dye at day 149
post-inoculation, while untreated mice started at day 154
post-inoculation. Throughout the observation period,
there was a clear tendency of IL-12 and IL-18 treated mice
to die before the untreated mice. Mean survival times (±
SEM) were 161,1 ± 1,5 for IL-12 and IL-18 treated mice
and 166,3 ± 1,7 for untreated mice. Survival curve analysis
indicated a statistically significant difference between the
two groups (two-tailed P value < 0,05).
At 90 days post-inoculation PrPSc accumulation was quite
variable among individual mice (Fig. 4A); mice inocu-
lated with IL-12 and IL-18, however, showed a more pro-
nounced accumulation of PrPSc  in brain tissue than
untreated mice, with a statistical analysis that closely
approached the significance (two-tailed P value = 0,054,
Fig. 4B). To further corroborate this finding and due to the
variability observed, we pooled the brain homogenates of
mice sacrificed at 90 d.p.i. and compared PrPSc in the
IFN-γ production Figure 1
IFN-γ production. IFN-γ production, detected in brain homogenates, from untreated mice or mice intracerebrally inoculated 
with saline or IL-12 and IL-18, sacrificed at different time after treatment. * values statistically different from those obtained in 
mice treated with saline at the same time.
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pooled homogenates of the two groups. The pooled
homogenates from the IL-12/IL-18 treated mice showed a
more than doubled PrPSc content compared with that of
untreated mice (data not shown).
The PrPSc brain accumulation was very invariable in termi-
nally sick mice and similar pattern and quantity of PrPSc
deposition were observed in IL-12 and IL-18 treated and
untreated mice (Fig. 4C and 4D).
The results obtained using a single dose of scrapie inocu-
lum were then re-evaluated using the same dose of
cytokines and different doses of scrapie inocula (data not
shown). This experiment confirmed that the exogenous
treatment of IL-12 and IL-18 induced a reduction of sur-
vival time in mice inoculated with 10-2, 10-3 and 10-4 ME7
dilutions.
Discussion
IL-12 is a heterodimeric interleukin produced by antigen
presenting cells as macrophages, dendritic cells or micro-
glia. It plays a central role in cell-mediated immune
response. Recent findings show that IL-12 actively plays
an important role also in central nervous system but its
influence seems to be a double-edged sword having both
a detrimental effect observed in experimental allergic
encephalomyelitis or multiple sclerosis [30] and a protec-
tive role against neurotropic viruses [31]. IL-12 acts in a
paracrine fashion in the cascade of events that lead to a
Th1-like immune response but it has been seen that it may
play also an autocrine effect on microglia [32,33].
IL-18 is a pleiotropic pro-inflammatory cytokine pro-
duced by antigen presenting cells. It is a newly-described
cytokine that has been shown to be essential for IFN-γ
production [34]. There is no direct evidence of autocrine
effect of IL-18 on central nervous system. However, the
finding that mouse peritoneal macrophages stimulated in
vitro with recombinant murine IL-18 induced TNF-α, IL-
1α and IL-1β [35], suggests that IL-18 can exert also an
autocrine effect on microglia which represent the main
population of macrophage-like cells in the brain. This fact
TNF-α production Figure 2
TNF-α production. TNF-α production detected in brain homogenates, from untreated mice or mice intracerebrally inocu-
lated with saline or IL-12 and IL-18, sacrificed at different time after treatment. *values statistically different from those 
obtained in mice treated with saline at the same time
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is further corroborated by the results of recent studies
showing that IL-18-gene-disrupted mice had impaired
microglial activities [36]. Due to the well-known synergis-
tic effect of IL-12 and IL-18 [29], we firstly tested the effect
of the direct intracerebral administration of these two
cytokines.
We found that intracerebral administration of IL-12 and
IL-18 induces a production of TNF-α and IFN-γ in brain
tissue, at 6 and 24 hours after administration. In addition,
we found that IL-12 and IL-18 induced also the stimula-
tion of macrophage-like cells.
These findings do not clarify the complete scenario of
events following inoculation but support the concept that
IL-12 and IL-18 are able to induce a broad spectrum of
effects, comprising the activation of microglia as showed
by the increased cytokine production and especially by
increased immunoreactivity to F4/80 in brain tissues. It is
unclear if the cellular activation is due to direct effect of IL-
12 and IL-18, mimicking an autocrine pattern or it is the
effect of activated T lymphocytes that, in turn, produce
IFN-γ and hence stimulate microglia through a classic
paracrine pattern.
We further investigated the effect of combined IL-12 and
IL-18 on scrapie pathogenesis. We found that a single
intracerebral cytokine administration, contemporary to
the scrapie inoculum, is able to affect the course of scrapie
pathogenesis. In mice inoculated with high prion dose
(10% ME7-derived brain homogenate), the treatment
with IL-12/IL-18 induced a small but statistically signifi-
cant reduction of mean survival time. This effect was par-
alleled by an increased brain accumulation of PrPSc at 90
days post inoculation, but not at the terminal stage of the
disease. Our findings complement those obtained by
Thackray et al. [37], who found that IL-10 knock-out mice
show a marked reduction of incubation period intracere-
bral or peripheral scrapie infection. IL-12 and IL-18 on
one side and IL-10 on the other, in fact, can be considered
counteracting molecules in the macrophage-like cells.
In our study we did not observe any effect on PrPC expres-
sion after intracerebral administration of IL-12 and IL-18.
We assessed PrPC expression by measuring its content in
brain homogenates, a method that mostly account for
neuronal expression of PrPC, but can be not adequate for
measuring subtle variations in other cell types of the
brain. In scrapie, incubation time can be markedly
reduced in transgenic mice overexpressing PrPC [38] and
prion protein expression has been reported to be
cytokine-inducible in some human neural cell lines [39].
The prion protein is expressed at high levels in the central
nervous system and this mainly depends on high expres-
sion in neurons [40], but PrPC is also expressed in micro-
glia and astrocytes [41,42]. Taken together these
considerations let us to conclude that the reduction of the
incubation period we observed in mice treated with IL-12
and IL-18 is not explainable by modification of PrPC
expression in neurons; however we can not exclude that
IL-12 and IL-18-activated microglia overexpress PrPC, as it
is true for IFN-γ-activated human CD14+ monocytes [43].
On the basis of the effect observed after intracerebral
administration of IL-12 and IL-18, we can suppose that IL-
12 and IL-18-activated microglia favor the progression of
Survival of scrapie infected mice Figure 3
Survival of scrapie infected mice. Survival times after 
intracerebrally injection of scrapie ME7-derived brain 
homogenate (10% w/v in sterile saline) of mice treated with 
IL-12 and IL-18 (circles) or with saline (squares).
Table 1: Reactivity to GFAP and F4/80 in brains from mice inoculated with saline and IL-12/IL-18.
Astrocytes (GFAP) Microglia (F4/80)
Treatment 6 hours 24 hours 6 hours 24 hours
Saline 4/16 (25%) 2/14 (14,3%) 1/16 (6,2%) 2/14 (14,3%)
IL-12/IL-18 2/16 (12,5%) 5/15 (33,3%) 7/15 (46,7%) 8/14 (57,1%)
Mice were sacrificed 6 or 24 hours after intracerebral inoculation. Observation was made in different areas of brain, by different independent 
observers. Numbers are referred to the fields where it was observed an increase of reactivity upon the examined fields.BMC Veterinary Research 2006, 2:37 http://www.biomedcentral.com/1746-6148/2/37
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the disease when high prion doses were used. In this sce-
nario it is possible to postulate two different mechanisms
that can explain our findings. The first is that activated
microglia have an increased capability to uptake scrapie
agents and to present them to neurons, implying that
microglia act as bridge to reach neurons. There is evi-
dence, in fact, that besides lympho-reticular cells
[11,44,45] also mononuclear phagocytic cells [46,47]
support replication of prions and may mediate transmis-
sion of infection from periphery to central nervous sys-
tem. In addition, more recent findings indicate that a
localized early inflammatory response takes place within
the central nervous system of mice intracerebrally inocu-
lated with brain homogenates from normal or scrapie
infected mice [48,21]. It suggests that inflammatory cells,
such as microglia, can act in the early response to prion
invasion after intracerebral scrapie inoculation. Finally, it
has been found that purified microglia from Creutzfeldt-
Jakob Disease-infected mice show infectivity comparable
to that of starting brain homogenate even if express less
PrP [49]. The second mechanism is that IL-12 and IL-18
administration increases the ability of microglia to dam-
age central nervous system, which led to a more preco-
cious neuronal dead. This hypothesis is based on the
finding that widespread neuronal degeneration is likely to
induce microglial activation which, in turn, may further
contribute to neurotoxicity [50] by releasing inflamma-
tory cytokines such as IL-1, IL-6 and TNF-α that contribute
to the development of pathological findings [27]. It is
worth noting that the reduction of the incubation period
observed was obtained with a single interleukin adminis-
tration at the time of scrapie inoculation. It is difficult to
postulate that such a treatment would exert its effects in
the late phase of the disease, i.e. 3 to 5 months later. It is
our opinion, therefore, that these findings give credit to
the hypothesis that IL-12 and IL-18-activated microglia
are more efficient to uptake and to present scrapie agents
to neurons.
Incubation time of scrapie is inversely proportional to the
logarithm of the concentration of the inoculum as
reported by us and others [51,52]. This pattern would be
consistent with a process of exponential growth of the
scrapie agent that cause disease onset at a threshold level.
Our results are reminiscent of such a process because we
observed a more pronounced accumulation of PrPSc at 90
days post-inoculation and a decreased incubation time in
IL-12 and IL-18-treated mice compared to the control ani-
PrPsc evaluation Figure 4
PrPsc evaluation. Western-blot patterns (A, C) and semiquantitative analysis (B, D) of brain homogenates of mice sacrificed 
at 90 days after infection (A, B) or terminally sick (C, D).BMC Veterinary Research 2006, 2:37 http://www.biomedcentral.com/1746-6148/2/37
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mals. On the other hand, all mice with terminal disease
showed very similar levels of PrPSc brain accumulation
irrespective of treatment, implying that cytokines admin-
istration did not interfere in the interplay among scrapie
agent replication, PrPSc  accumulation and neuronal
degeneration in the late phase of the disease. These find-
ings strongly indicate that IL-12 and IL-18 inoculated
mice developed the disease before control mice because of
a faster kinetic of PrPSc accumulation and a more rapid
progression of the disease.
Conclusion
we provided evidence that intracerebral administration of
IL-12 and IL-18 stimulated microglia in central nervous
system and that a single treatment contemporary to
intracerebral scrapie injection is able to affect the course of
scrapie infection. Our findings provide insight into the
process involved in the central nervous system pathogen-
esis of scrapie and contribute to shed renewed light on the
interplay between immune system and scrapie agents.
Methods
Animals and pathogen
The ME7 strain was kindly provided by Moira Bruce of the
Neuropathogenesis Unit at Edinburgh.
C57BL/6 female mice were obtained from Charles River,
Italy, and used in the experiments at nine weeks of age.
They were maintained in barrier housing with filtered
inflow air in a restricted-access room and in pathogen-
limited conditions. They were fed a commercial diet and
water was provided ad libitum. All mice were acclimatised
for 1 week prior to experimentation. In the first set of
experiments, mice were employed in groups consisting of
5 animals each. Mice were anaesthetised and injected ster-
eotactically in striatum (with coordinates: Bregma 0.38
mm)(Keith B.J. Franklin and Gorge Paxinos – The Mouse
Brain in Stereotaxic Coordinates. Academic Press) with 20
μl of mouse recombinant Interleukin-12 (IL-12) (1000
ng) and/or IL-18 (500 ng), purchased from R&D Systems,
MN, USA. Controls consisted of injected with sterile
saline, or uninoculated mice. Following treatment, mice
were allowed to recover under a warm lamp. Mice were
sacrificed at 6 and 24 hours after treatment and brains
were rapidly removed. Brains were longitudinally cut, for
each brain one hemisphere was fixed in buffered formalin
and the other was snap frozen on liquid nitrogen.
Immunological analyses
The frozen hemispheres were successively weighed and
homogenised (20% W/V) in PBS containing protease
inhibitors (Complete Mini, Roche). Mouse Tumor Necro-
sis Factor-alfa (TNF-α), and Interferon-γ (IFN-γ) were
detected in duplicate in brain homogenates by enzime-
linked immunosorbent assay (ELISA) according to the
manufactures instructions of a commercial kit (R&D Sys-
tems, MN). For PrPC  detection, 50 μl of each brain
homogenate was diluted to 200 μl in lysis buffer (PBS
containing 0,5% Nonidet P40 and 0,5% Sodium Deoxy-
cholate, final concentration) and incubated 20 min at
room temperature. The samples were then centrifuged at
1000 g for 5 min in a microcentrifuge and supernatants
were added with equal volumes of 2× NU-PAGE sample
buffer (Invitrogen), heated at 95°C for 10 min, centri-
fuged in a microcentrifuge at 12,000 rpm for 5 min and
subsequently subjected to electrophoresis and western
blotting as described below.
The other hemispheres were fixed for 5 days in 10% buff-
ered formalin. Coronal sections corresponding to basal
nuclei, thalamus, cerebellum and brain stem were embed-
ded in paraffin wax. Serial sections were performed at 5
μm and stained with Haematoxylin-Eosin (HE) or sub-
mitted to immunolabelling (IHC). For the latter, two dif-
ferent tests were performed in order to detect astrocyte
proliferation and activation using the mAb anti-glial
fibrillar acidic protein (GFAP) and to detect microglia
activation using the mAb anti-F4/80.
For GFAP immunolabelling, deparaffinized sections were
treated with 3% H2O2 in methanol for 10 min at room
temperature to abolish endogenous peroxidase activity
and, after heat induced antigen retrieval (citrate buffer
0,01 M, pH 6.0, 1 × 5 min in microwave oven, 750 watts),
incubated 30 min with polyclonal rabbit anti cow GFAP
[1:500, Dako, Glostrup, Denmark]. Immunoreactivity
was detected with avidin-biotin-complex (ABC) method
[LSAB+®, Dako Corporation, San Francisco, USA] as sug-
gested by the suppliers.
For F4/80, after heat induced antigen retrieval treatment
(citrate buffer 0,01 M, pH 6.0, 20 min, in steamer), mon-
oclonal rat anti F4/80 antigen [1:100, Serotec Ltd, Oxford,
UK] was applied for 30 min. Immunolabelling was per-
formed with a Polymer-Immunocomplex method [Pic-
ture™ Plus, Zymed Laboratories Inc., San Francisco, USA],
in accordance with the manufacturer's recommendations.
Reactions were visualized with 3, 3' diaminobenzidine
[Dako Corporation, Carpinteria, USA] and Mayer's hae-
matoxylin was used as counter stain. Tris-buffered saline
(TBS, 50 mM Tris-HCl, 150 mM NaCl, pH 7.6 with 0.05%
Tween 20) was used as washing and antibody diluent
buffer. Slides were analysed by two independent opera-
tors who ranked the degree of reactivity in 20 microscopic
fields.
In the second set of experiments two groups of 22 mice
were anaesthetised and injected stereotactically in stria-
tum (with coordinates: Bregma 0.38 mm) (Keith B.J. Fran-BMC Veterinary Research 2006, 2:37 http://www.biomedcentral.com/1746-6148/2/37
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klin and Gorge Paxinos – The Mouse Brain inStereotaxic
Coordinates. Academic Press) with 20 μl of ME7-derived
brain homogenate (10% w/v in sterile saline) containing
IL-12 (1000 ng) and IL-18 (500 ng) or sterile saline. Six
mice of each group were sacrificed at 90 days post-inocu-
lation to evaluate the presence of PrPSc. The remaining 16
mice for each group were clinically scored weekly and
observed daily from the first appearance of clinical signs
up to terminal disease, to determine the survival times.
Brains from mice sacrificed at 90 days after infection or
dead due to scrapie were removed, snap frozen in liquid
nitrogen and kept at -80°C until use. The frozen brains
were weighed and homogenised (10% w/v) in PBS con-
taining 2% Sarcosyl. After incubation at room tempera-
ture for 20 min, proteinase K was added to 50 μl from
each sample to a final concentration of 200 μg/ml. Sam-
ples were then incubated for 1 hour at 37°C with gentle
shaking followed by the addition of PMSF to a final con-
centration of 3 mM. Finally, equal volumes of 2× NU-
PAGE sample buffer (Invitrogen) were added and the
samples were heated at 95°C for 10 min, centrifuged in a
microcentrifuge at 12,000 rpm for 5 min and subse-
quently subjected to electrophoresis and western blotting.
Ten μl of samples were loaded onto 12% bis-Tris polyacr-
ylamide gels (Invitrogen). Electrophoresis was carried out
at 200 V for 40 min and Western blotting performed on
polyvinylidene difluoride membranes (Millipore) at 100
mA per gel for 40 min in a semidry blotting apparatus
(Trans-Blot SD, Bio-Rad). The blots were blocked in PBS
containing 0.1% Tween 20 and 5% non-fat milk powder
for 1 h. Both, PrPC and PrPSc were detected with the mon-
oclonal antibody SAF84 (0,2 μg/ml, provided by J. Grassi,
CEA, France), for 1 h at room temperature. Horseradish
peroxidase-conjugated goat anti-mouse IgG (1:5,000 for 1
h, Sigma) was used as secondary antibody. The mem-
branes were developed with the enhanced chemilumines-
cence method (Supersignal, West Femto, Pierce).
Chemiluminescence detection was performed with the
VersaDoc imaging system (Bio-Rad) and signals were
quantified with the Quantity One software (Bio-Rad).
Statistical analysis
Differences of TNF-α and IFN-γ production was evaluated
by analysis of variance with significance when P ≤ 0.05.
Differences in PrPSc accumulation or PrPC expression were
assessed by unpaired t test by calculation of two-tailed P
values. The significance of different mortality curves was
assessed by survival curve analysis, calculated with the
Prism software (Graphpad), which compares survival
curves using the logrank test (Mantel-Haenszel test).
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